Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

被引:8
作者
Fraune, Christoph [1 ]
Harms, Luisa [1 ]
Buescheck, Franziska [1 ]
Hoeflmayer, Doris [1 ]
Tsourlakis, Maria Christina [1 ]
Clauditz, Till S. [1 ]
Simon, Ronald [1 ]
Moeller, Katharina [1 ]
Luebke, Andreas M. [1 ]
Moeller-Koop, Christina [1 ]
Steurer, Stefan [1 ]
Hube-Magg, Claudia [1 ]
Sauter, Guido [1 ]
Weidemann, Soeren [1 ]
Lebok, Patrick [1 ]
Dum, David [1 ]
Kind, Simon [1 ]
Minner, Sarah [1 ]
Izbicki, Jakob R. [2 ]
Schlomm, Thorsten [3 ]
Huland, Hartwig [4 ]
Heinzer, Hans [4 ]
Burandt, Eike [1 ]
Haese, Alexander [4 ]
Graefen, Markus [4 ]
Schroeder, Cornelia [2 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Martinistr 52, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Gen Visceral & Thorac Surg Dept, Hamburg, Germany
[3] Charite Univ Med Berlin, Dept Urol, Berlin, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Martini Clin, Prostate Canc Ctr, Hamburg, Germany
关键词
TFAP2D; prostate cancer; genomic instability; prognosis; immunohistochemistry; tissue micro array; EARLY PSA RECURRENCE; GENOMIC DELETION; POOR-PROGNOSIS; TISSUE MICROARRAYS; FACTOR AP-2-GAMMA; SUPPRESSOR GENES; EXPRESSION; AP-2; MARKER; FAMILY;
D O I
10.1186/s10020-020-00148-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background TFAP2D is a transcription factor important for modulating gene expression in embryogenesis. Its expression and prognostic role in prostate cancer has not been evaluated. Methods Therefore, a tissue microarray containing 17,747 prostate cancer specimens with associated pathological, clinical, and molecular data was analyzed by immunohistochemistry to assess the role of TFAP2D. Results TFAP2D expression was typically increased in prostate cancer as compared to adjacent non-neoplastic glands. TFAP2D staining was considered negative in 24.3% and positive in 75.7% of 13,545 interpretable cancers. TFAP2D staining was significantly linked to advanced tumor stage, high classical and quantitative Gleason grade, lymph node metastasis, and a positive surgical margin (p <= 0.0045). TFAP2D positivity was more common in ERG fusion positive (88.7%) than in ERG negative cancers (66.8%; p < 0.0001). Subset analyses in 3776 cancers with and 4722 cancers without TMPRSS2:ERG fusion revealed that associations with tumor phenotype and patient outcome were largely driven by the subset of ERG negative tumors. Multivariate analysis did not identify TFAP2D protein expression levels as a robust independent prognostic parameter. Positive TFAP2D immunostaining was significantly associated with 10 of 11 previously analyzed chromosomal deletions in ERG negative cancers (p <= 0.0244 each) indicating that elevated TFAP2D expression parallels genomic instability in prostate cancer. Conclusion These data demonstrate that TFAP2D protein overexpression is linked to prostate cancer progression and genomic instability in ERG negative prostate cancers.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer
    Kissick, Haydn Thomas
    Sanda, Martin George
    Dunn, Laura Kathleen
    Arredouani, Mohamed Simo
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (12) : 1831 - 1840
  • [32] Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and tumour molecular subtypes in prostate cancer management
    Bugoye, Fidelis Charles
    Torrorey-Sawe, Rispah
    Biegon, Richard
    Dharsee, Nazima
    Mafumiko, Fidelice
    Kibona, Herry
    Aboud, Said
    Patel, Kirtika
    Mining, Simeon
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [33] Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis
    Robert, Gregoire
    Jannink, Sander
    Smit, Frank
    Aalders, Tilly
    Hessels, Daphne
    Cremers, Ruben
    Mulders, Peter F.
    Schalken, Jack A.
    PROSTATE, 2013, 73 (02) : 113 - 120
  • [34] TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis
    Rostad, Kari
    Hellwinkel, Olaf J. C.
    Haukaas, Svein A.
    Halvorsen, Ole J.
    Oyan, Anne M.
    Haese, Alexander
    Budaus, Lars
    Albrecht, Heiko
    Akslen, Lars A.
    Schlomm, Thorsten
    Kalland, Karl-Henning
    APMIS, 2009, 117 (08) : 575 - 582
  • [35] Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer
    Weier, Christopher
    Haffner, Michael C.
    Mosbruger, Timothy
    Esopi, David M.
    Hicks, Jessica
    Zheng, Qizhi
    Fedor, Helen
    Isaacs, William B.
    De Marzo, Angelo M.
    Nelson, William G.
    Yegnasubramanian, Srinivasan
    JOURNAL OF PATHOLOGY, 2013, 230 (02) : 174 - 183
  • [36] Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells
    Polson, Euan S.
    Lewis, John L.
    Celik, Hamza
    Mann, Vincent M.
    Stower, Michael J.
    Simms, Matthew S.
    Rodrigues, Greta
    Collins, Anne T.
    Maitland, Norman J.
    NATURE COMMUNICATIONS, 2013, 4
  • [37] Apurinic/apyrimidinic endonuclease 1 (APE1/Ref-1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion
    Juhnke, Manuela
    Heumann, Asmus
    Chirico, Viktoria
    Hoeflmayer, Doris
    Menz, Anne
    Hinsch, Andrea
    Hube-Magg, Claudia
    Kluth, Martina
    Lang, Dagmar S.
    Moeller-Koop, Christina
    Sauter, Guido
    Simon, Ronald
    Beyer, Burkhard
    Pompe, Raisa
    Thederan, Imke
    Schlomm, Thorsten
    Luebke, Andreas M.
    MOLECULAR CARCINOGENESIS, 2017, 56 (09) : 2135 - 2145
  • [38] Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth
    Obinata, Daisuke
    Ito, Akiko
    Fujiwara, Kyoko
    Takayama, Ken-Ichi
    Ashikari, Daisaku
    Murata, Yasutaka
    Yamaguchi, Kenya
    Urano, Tomohiko
    Fujimura, Tetsuya
    Fukuda, Noboru
    Soma, Masayoshi
    Watanabe, Takayoshi
    Nagase, Hiroki
    Inoue, Satoshi
    Takahashi, Satoru
    CANCER SCIENCE, 2014, 105 (10): : 1272 - 1278
  • [39] Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
    Nam, R. K.
    Sugar, L.
    Yang, W.
    Srivastava, S.
    Klotz, L. H.
    Yang, L-Y
    Stanimirovic, A.
    Encioiu, E.
    Neill, M.
    Loblaw, D. A.
    Trachtenberg, J.
    Narod, S. A.
    Seth, A.
    BRITISH JOURNAL OF CANCER, 2007, 97 (12) : 1690 - 1695
  • [40] Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
    R K Nam
    L Sugar
    W Yang
    S Srivastava
    L H Klotz
    L-Y Yang
    A Stanimirovic
    E Encioiu
    M Neill
    D A Loblaw
    J Trachtenberg
    S A Narod
    A Seth
    British Journal of Cancer, 2007, 97 : 1690 - 1695